Mylan's Mauro elected chair of GPhA
This article was originally published in SRA
Tony Mauro, president of Mylan North America and the company's Mylan Pharmaceuticals subsidiary, has been elected to serve as chair of the Generic Pharmaceutical Association's board of directors1. His term as chair will last one year. He previously served two one-year terms as vice-chair of the association. Mr Mauro has worked at Mylan for 15 years, having previously served as chief operating officer, vice-president of strategic development and vice-president of sales before becoming president.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.